Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells

M Düfer1, P Krippeit-Drews, N Lembert

  • 1Department of Pharmacology, Institute of Pharmacy, University of Tübingen, Tübingen, Germany.

Molecular Pharmacology
|September 20, 2001
PubMed

Insights

Cyclosporin A (CsA) impairs glucose tolerance by disrupting pancreatic B-cell function. CsA inhibits mitochondrial permeability transition pores, halting calcium oscillations essential for insulin secretion and leading to diabetes.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Pharmacology

Background:

  • Organ transplant patients on cyclosporin A (CsA) often develop impaired glucose tolerance and diabetes.
  • The exact mechanism by which CsA induces diabetogenic effects remains incompletely understood.

Purpose of the Study:

  • To investigate the in vitro effects of CsA on glucose-induced insulin secretion in mouse pancreatic islets.
  • To elucidate the cellular mechanisms underlying CsA-induced impairment of B-cell function.

Main Methods:

  • Isolated mouse pancreatic islets were treated with CsA (2-5 microM).
  • Measurements included glucose-induced insulin secretion, cytoplasmic free Ca(2+) concentration ([Ca(2+)](c)) oscillations, and cell membrane potential.
  • Effects were compared with other calcineurin inhibitors and assessed for ATP depletion and mitochondrial membrane potential (Delta Psi) changes.

Main Results:

  • CsA (2-5 microM) diminished glucose-induced insulin secretion by inhibiting [Ca(2+)](c) oscillations in pancreatic B-cells.
  • This effect was independent of calcineurin inhibition and direct L-type Ca(2+) channel blockade.
  • CsA inhibited mitochondrial permeability transition pore (PTP) and mitochondrial membrane potential oscillations, but not cellular ATP levels.

Conclusions:

  • CsA impairs pancreatic B-cell function by inhibiting the mitochondrial PTP, disrupting calcium oscillations necessary for insulin secretion.
  • This mechanism explains the diabetogenic side effects of CsA in transplant patients.
  • CsA targets distinct pathways for its immunosuppressive and diabetogenic actions.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...